Hydroxychloroquine in Subclinical Autoimmunity – Evidence Summary

1. Evidence Gap for Preventive Use

2. Predictive Value of Isolated Autoantibodies

3. Safety Concerns in Asymptomatic Patients

Retinal Toxicity

Other Adverse Effects

4. Monitoring Requirements for Hydroxychloroquine

Evidence level: moderate (expert consensus). 6, 7

5. Indications for Established Autoimmune Disease (Not Subclinical)